kabutan

Takeda Pharmaceutical Company Limited(4502) Summary

4502
TSE Prime
Takeda Pharmaceutical Company Limited
5,289
JPY
+71
(+1.36%)
Apr 28, 3:30 pm JST
33.22
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
5,258
Apr 28, 11:39 pm JST
Summary Chart Historical News Financial Result
PER
54.2
PBR
1.09
Yield
3.78%
Margin Trading Ratio
18.16
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
5,292 JPY 33.20 USD
Previous Close Apr 27
5,218 JPY 32.73 USD
High Apr 28, 9:00 am
5,295 JPY 33.22 USD
Low Apr 28, 9:02 am
5,224 JPY 32.78 USD
Volume
3,363,300
Trading Value
0.02T JPY 0.11B USD
VWAP
5276.53 JPY 33.14 USD
Minimum Trading Value
528,900 JPY 3,322 USD
Market Cap
8.42T JPY 0.05T USD
Number of Trades
4,133
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
5,710
1-Year High May 12, 2025
17,590
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 458,800 914,600 1.99
Apr 17, 2026 434,400 746,200 1.72
Apr 10, 2026 451,600 639,400 1.42
Apr 3, 2026 363,900 494,200 1.36
Mar 27, 2026 496,600 521,400 1.05
Company Profile
Takeda Pharmaceutical Company Limited is a leading pharmaceutical company. With the acquisition of Shire, it has become a global industry leader. The company focuses on prescription drugs and is strengthening its development of new cancer medications.
Sector
Pharmaceuticals
Takeda Pharmaceutical Company Limited's main business is the research, development, manufacturing, and sales of pharmaceuticals, with a focus on key business areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company's research and development efforts are concentrated on three areas: innovative biopharmaceuticals in the priority disease areas of gastroenterology and inflammatory diseases, neuroscience, and oncology, along with plasma-derived therapies and vaccines. Takeda is also committed to rare diseases. The company invests in new research and development capabilities and next-generation platforms, leveraging data and digital technologies to enhance innovation quality and accelerate execution. In Japan, Takeda conducts all operations from research and development to sales in-house, while overseas subsidiaries and affiliates handle manufacturing and sales functions in their respective countries.